As HIF2A is stabilised in renal cancer by tumour-initiating mutations in the VHL tumour suppressor, these data provide detailed insight into the mechanisms of interaction between cancer driver mutations and epigenetic events, and how this leads to cancer progression. This evidence concerns the gene VHL and cancer.